Related Experiment Videos
CD26 in T-cell lymphomas: a potential clinical role?
S Verstovsek1, F Cabanillas, N H Dang
1Department of Lymphoma/Myeloma, University of Texas, M. D. Anderson Cancer Center, Houston, USA.
Oncology (Williston Park, N.Y.)
|July 11, 2000
Summary
This study investigates pentostatin for relapsed T-cell lymphomas, focusing on CD26 expression as a potential treatment marker. It aims to improve outcomes for aggressive T-cell lymphomas by targeting adenosine deaminase.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- T-cell non-Hodgkin's lymphomas are diverse, with initial presentation site influencing prognosis.
- CD26, crucial for T-cell function and adenosine deaminase binding, is a potential marker for aggressive T-cell lymphomas.
Purpose of the Study:
- To evaluate pentostatin, an adenosine deaminase inhibitor, in relapsed/refractory T-cell lymphomas.
- To assess the role of CD26 expression in predicting treatment response to pentostatin.
Main Methods:
- Initiation of a phase II clinical trial at M. D. Anderson Cancer Center.
- Treatment of relapsed/refractory T-cell lymphomas with pentostatin.
- Correlation of treatment outcomes with CD26 expression levels.
Main Results:
- The study is evaluating the efficacy of pentostatin in T-cell lymphoma patients.
- CD26 expression is being analyzed in relation to treatment response.
Conclusions:
- Translating CD26/adenosine deaminase biology into clinical practice for T-cell lymphomas.
- Developing targeted therapies for T-cell lymphomas based on CD26 expression.